Novartis has recalled a single lot of Diovan, its brand-name version of the blood pressure drug valsartan, after the tablets failed a laboratory test that measures how they break down in the body.
The recall covers Diovan 160 mg tablets in 90-count bottles, lot number AV5913C, with an expiration date of June 2027. Novartis initiated the action on August 4, and the Food and Drug Administration classified it as a Class II recall on August 7, publishing the entry in its weekly enforcement report on August 8. The tablets were manufactured by Patheon Manufacturing Services in Greenville, North Carolina, and distributed by Novartis Pharmaceuticals Corporation in Hanover, New Jersey.
